This article chronicles a didactic encounter between an ethics-minded physician-scientist and a personified genome editing technology called clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins, commonly abbreviated as CRISPR/Cas, or simply CRISPR. The interview considers clinically and ethically relevant questions about this technology related to patient safety, therapeutic efficacy, equitable access, and global governance of humanity's genetic legacy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/amajethics.2019.1079 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!